Xavier Garcia-Moll, Lorenzo Fácila, Pedro Conthe, Antonio Zapata, Remei Artigas, Vicente Bertomeu, José Ramón González-Juanatey
INTRODUCTION AND OBJECTIVES: Beta-blocker treatment has a class I indication, level of evidence A, in guidelines for the treatment of heart failure, ischemic heart disease, and atrial fibrillation. However, beta-blocker use continues to be less than optimal. In this study, beta blocker use in Spain is analyzed in patients with heart failure, ischemic heart disease, and atrial fibrillation. METHODS: Observational, epidemiologic, cross-sectional, multicenter study including 1608 patients with heart failure, ischemic heart disease, and/or atrial fibrillation, recruited in 150 healthcare centers by cardiologists and internal medicine specialists...
October 2011: Revista Española de Cardiología